Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection With Recurrent/Progressive High-grade Glioma.

NCT06763965 is registered in ClinicalTrials.gov with Beijing Bio-Targeting Therapeutics Technology Co., Ltd as lead sponsor.

NCT NCT06763965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06763965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection With Recurrent/Progressive High-grade Glioma.
Lead sponsor
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase
Phase 1/2
Overall status
Enrolling by invitation
Start date
November 26, 2024
Completion date
July 31, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent high-grade glioma